BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 26853911)

  • 21. Protein Nanoparticle Charge and Hydrophobicity Govern Protein Corona and Macrophage Uptake.
    Pustulka SM; Ling K; Pish SL; Champion JA
    ACS Appl Mater Interfaces; 2020 Oct; 12(43):48284-48295. PubMed ID: 33054178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amphoteric natural starch-coated polymer nanoparticles with excellent protein corona-free and targeting properties.
    Huang B; Yang Z; Fang S; Li Y; Zhong Z; Zheng R; Zhang J; Wang H; Wang S; Zou Q; Wu L
    Nanoscale; 2020 Mar; 12(10):5834-5847. PubMed ID: 32068222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How Corona Formation Impacts Nanomaterials as Drug Carriers.
    Gupta MN; Roy I
    Mol Pharm; 2020 Mar; 17(3):725-737. PubMed ID: 31939673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cloaking nanoparticles with protein corona shield for targeted drug delivery.
    Oh JY; Kim HS; Palanikumar L; Go EM; Jana B; Park SA; Kim HY; Kim K; Seo JK; Kwak SK; Kim C; Kang S; Ryu JH
    Nat Commun; 2018 Oct; 9(1):4548. PubMed ID: 30382085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent Developments in the Design of Non-Biofouling Coatings for Nanoparticles and Surfaces.
    Sanchez-Cano C; Carril M
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32028729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the Factors Influencing Chitosan-Based Nanoparticles-Protein Corona Interaction and Drug Delivery Applications.
    Moraru C; Mincea M; Menghiu G; Ostafe V
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Protein Corona Does Not Influence Receptor-Mediated Targeting of Virus-like Particles.
    Zackova Suchanova J; Hejtmankova A; Neburkova J; Cigler P; Forstova J; Spanielova H
    Bioconjug Chem; 2020 May; 31(5):1575-1585. PubMed ID: 32329599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of surface chemistry in serum protein corona-mediated cellular delivery and gene silencing with lipid nanoparticles.
    Chen D; Ganesh S; Wang W; Amiji M
    Nanoscale; 2019 May; 11(18):8760-8775. PubMed ID: 30793730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carbohydrate-Based Nanocarriers Exhibiting Specific Cell Targeting with Minimum Influence from the Protein Corona.
    Kang B; Okwieka P; Schöttler S; Winzen S; Langhanki J; Mohr K; Opatz T; Mailänder V; Landfester K; Wurm FR
    Angew Chem Int Ed Engl; 2015 Jun; 54(25):7436-40. PubMed ID: 25940402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interface of physics and biology: engineering virus-based nanoparticles for biophotonics.
    Wen AM; Infusino M; De Luca A; Kernan DL; Czapar AE; Strangi G; Steinmetz NF
    Bioconjug Chem; 2015 Jan; 26(1):51-62. PubMed ID: 25541212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological effects of formation of protein corona onto nanoparticles.
    Mishra RK; Ahmad A; Vyawahare A; Alam P; Khan TH; Khan R
    Int J Biol Macromol; 2021 Apr; 175():1-18. PubMed ID: 33508360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles.
    Hadjidemetriou M; Al-Ahmady Z; Kostarelos K
    Nanoscale; 2016 Apr; 8(13):6948-57. PubMed ID: 26961355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preservation of the soft protein corona in distinct flow allows identification of weakly bound proteins.
    Weber C; Simon J; Mailänder V; Morsbach S; Landfester K
    Acta Biomater; 2018 Aug; 76():217-224. PubMed ID: 29885856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In situ low-immunogenic albumin-conjugating-corona guiding nanoparticles for tumor-targeting chemotherapy.
    Li Z; Li D; Li Q; Luo C; Li J; Kou L; Zhang D; Zhang H; Zhao S; Kan Q; Liu J; Zhang P; Liu X; Sun Y; Wang Y; He Z; Sun J
    Biomater Sci; 2018 Sep; 6(10):2681-2693. PubMed ID: 30151516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The
    Nkanga CI; Chung YH; Shukla S; Zhou J; Jokerst JV; Steinmetz NF
    Biomater Sci; 2021 Oct; 9(21):7134-7150. PubMed ID: 34591046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma protein adsorption and biological identity of systemically administered nanoparticles.
    Chen D; Ganesh S; Wang W; Amiji M
    Nanomedicine (Lond); 2017 Sep; 12(17):2113-2135. PubMed ID: 28805542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanoparticles-cell association predicted by protein corona fingerprints.
    Palchetti S; Digiacomo L; Pozzi D; Peruzzi G; Micarelli E; Mahmoudi M; Caracciolo G
    Nanoscale; 2016 Jul; 8(25):12755-63. PubMed ID: 27279572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake.
    Mirshafiee V; Kim R; Park S; Mahmoudi M; Kraft ML
    Biomaterials; 2016 Jan; 75():295-304. PubMed ID: 26513421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biodistribution, pharmacokinetics, and blood compatibility of native and PEGylated tobacco mosaic virus nano-rods and -spheres in mice.
    Bruckman MA; Randolph LN; VanMeter A; Hern S; Shoffstall AJ; Taurog RE; Steinmetz NF
    Virology; 2014 Jan; 449():163-73. PubMed ID: 24418549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics.
    Bertrand N; Grenier P; Mahmoudi M; Lima EM; Appel EA; Dormont F; Lim JM; Karnik R; Langer R; Farokhzad OC
    Nat Commun; 2017 Oct; 8(1):777. PubMed ID: 28974673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.